Results 121 to 130 of about 1,367,754 (318)
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Pulmonary pleomorphic carcinoma treated with immune checkpoint inhibitors — a case series
Oncology in Clinical PracticePulmonary pleomorphic carcinoma (PPC) is a rare subtype of primary lung cancer, accounting for less than 2% of annual diagnoses. It is characterized by a low response rate to systemic treatment, an unusual molecular profile, an average high tumor ...
Anna Rudzińska +6 more
doaj +1 more source
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
Journal of the American Medical Association, 1915 Within the last three years a number of reports have appeared in the medical press which bear on the treatment of malignant growths in human beings by chemical preparations. The most persuasive and the most insistent claims have been made in connection with the colloidal solutions of certain metalloids and metals, notably selenium, vanadium and copper.
openaire +2 more sources
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Chemotherapy of small cell lung cancer
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer, and chemotherapy plays a central role in its treatment. In recent years, there have been major advances in the treatment landscape for small cell lung cancer, notably the advent of
Yeh, Chiachen
core
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
The current role of fluoropyrimidines in cancer chemotherapy
, 2018 The main aim of chemotherapy has always been to destroy tumor cells without necessarily affecting the normal cells, hence the need for more directly acting drugs.
Ezeibekwe, Nancy Chinonyerem
core